ENA 2022 Poster 332

Developing a Preclinical CD47 IHC Assay Using Patient-Like Samples for the Development of a Companion Diagnostic for CD47-Targeting Treatments

Xiaolong Tu, Likun Zhang, Weijie Chen, Dawei Wang, Jin Guo, Henry Li, Annie Xiaoyu An

Anti-CD47 antibodies and SIRPα fusion proteins are currently being developed for the treatment of various cancers. It is believed that CD47 expression on the surface of cancer cells is critical for the success of these therapies and if true, CD47 could become a predictive biomarker for the treatment of cancer and/or be developed as a companion diagnostic (CDx).

It is thus prudent to have a robust, practical, and relevant clinical testing assay that can measure CD47 expression in the clinic.

Download this Poster to Discover:

• How we developed a CD47 IHC assay that can potentially be used as a clinical testing assay using preclinical FFPE samples from PDX models

Download the Poster Now!